Catheter-related infections: It's all about biofilm

Topics in Advanced Practice Nursing

Volumn 5, Issue 3, 2005, Pages

  Ryder, Marcia A ^a  

^a Research and Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; ALCOHOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; EDETATE SODIUM; EDETIC ACID; ERYTHROMYCIN; GLYCOPEPTIDE; HYDROCHLORIC ACID; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TAUROLIDINE; TETRACYCLINE; TRIMETHOPRIM;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BACTERIUM CONTAMINATION; BIOFILM; BLOOD CULTURE; CATHETER INFECTION; CELL ADHESION; CELL SURFACE; CHILL; CLINICAL FEATURE; COLONY FORMING UNIT; CULTURE TECHNIQUE; FEVER; HUMAN; INFLAMMATION; MICROBIAL COLONIZATION; MICROBIAL GROWTH; MOLECULAR MECHANICS; OXYGEN CONSUMPTION; PATHOGENESIS; PHAGOCYTE; PSEUDOMONAS AERUGINOSA; RECEPTOR BINDING; STAPHYLOCOCCUS AUREUS; UPREGULATION;

EID: 25444507123     PISSN: 15352250     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Graves N. Economics and preventing hospital-acquired infection. Emerg Infect Dis. 2004;10:561-566.
2. Munch R. Robert Koch. Microbes Infect. 2003;5:69-74.
3. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-1322.
4. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis. 2001;33:1387-1392.
5. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 2003;112:1466-1477.
6. Manangan LP, Pearson ML, Tokars JI, Miller E, Jarvis WR. Feasibility of national surveillance of health-care-associated infections in home-care settings. Emerg Infect Dis. 2002;8:233-236.
7. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27:887-892.
8. O'Toole G. To build a biofilm. J Bacteriol. 2003;185:2687-2689.
9. Brown E, Wenzel RP, Hendley JO. Exploration of the microbial anatomy of normal human skin by using plasmid profiles of coagulase-negative staphylococci: search for the reservoir of resident skin flora. J Infect Dis. 1989;160:644-650.
10. Hendley JO, Ashe KM. Effect of topical antimicrobial treatment on aerobic bacteria in the stratum corneum of human skin. Antimicrob Agents Chemother. 1991;35:627-631.
11. Maki DG, Ringer M. Evaluation of dressing regimes for prevention of infection with peripheral intravenous catheters. Gauze, a transparent polyurethane dressing, and an iodophortransparent dressing. JAMA. 1987;258:2396-2403.
12. Ryder M. The role of biofilm in vascular catheter-related infections. N Dev Vasc Dis. 2001;2:15-25.
13. Cappelli G, Tetta C, Canaud B. Is biofilm a cause of silent chronic inflammation in haemodialysis patients? A fascinating working hypothesis. Nephrol Dial Transplant. 2005;19:1-4.
14. Vandecasteele SJ, Peetermans WE, Merckx R, Van Eldere J. Expression of biofilm-associated genes in Staphylococcus epidermidis during in vitro and in vivo foreign body infections. J Infect Dis. 2003;188:730-737.
15. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents. 1999;11:217-221.
16. Hoiby N, Johansen HK, Moser C, et al. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001;3:23-35.
17. Gilbert P, Maira-Litran T, McBain AJ, Rickard AH, Whyte FW. The physiology and collective recalcitrance of microbial biofilm communities. Adv Microb Physiol. 2002;46:203-256.
18. Kite P, Eastwood K, Sugden S, Percival SL. Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J Clin Microbiol. 2004;42:3073-3076.
19. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002;8:881-890.
20. Fux CA, Wilson S, Stoodley P. Detachment characteristics and oxacillin resistance of Staphylococcus aureus biofilm emboli in an in vitro catheter infection model. J Bacteriol. 2004;186:4486-4491.
21. Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol. 1997;30:1072-1078.
22. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532.
23. Leid JG, Shirtliff ME, Costerton JW, Stoodley AP. Human leukocytes adhere to, penetrate, and respond to Staphylococcus aureus biofilms. Infect Immun. 2002;70:6339-6345.
24. Gilbert P, Maira-Litran T, McBain AJ, Rickard AH, Whyte FW. The physiology and collective recalcitrance of microbial biofilm communities. Adv Microbial Physiol. 2002;46:203-256.
25. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167-193.
26. Rani SA, Pitts B, Stewart PS. Rapid diffusion of fluorescent tracers into Staphylococcus epidermidis biofilms visualized by time lapse microscopy. Antimicrob Agents Chemother. 2005;49:728-732.
27. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 2001;45:999-1007.
28. Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol. 2002;292:107-113.
29. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther. 2003;1:667-683.
30. Nystrom T. Aging in bacteria. Curr Opin Microbiol. 2002;5:596-601.
31. Tenover PC, Schaberg DR. Molecular biology of resistance. In: Bennett JV, Brachman PS, eds. Hospital Infections, 4th ed. Philadelphia, Pa: Lippincott-Raven; 1998:237-247.
32. Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol. 2003;57:677-701.
33. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol. 2004;186:8172-8180.
34. Roberts ME, Stewart PS. Modeling protection from antimicrobial agents in biofilms through the formation of persister cells. Microbiology. 2005;151:75-80.
35. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358:135-138.
36. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular devicerelated bloodstream infection. Ann Intern Med. 2005;142:451-466.
37. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis. 1993;168:400-407.
38. Raad I. Intravascular-catheter-related infections. Lancet. 1998;351:893-898.
39. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. Intensive Care Med. 2004;30:62-67.
40. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med. 1999;340:1-8.
41. Raad I, Hanna H. Nosocomial infections related to use of intravascular devices inserted for long-term vascular access. In: Mayhall C, ed. Hospital Epidemiology and Infection Control. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:165-172.
42. Hall K, Farr B. Diagnosis and management of long-term central venous catheter infections. J Vasc Interv Radiol. 2004;15:327-334.
43. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol. 2002;23:759-769.
44. Farr BM. Catheters, microbes, time, and gold standards. Ann Intern Med. 2004;140:62-64.
45. Pittet D, Chuard C, Rae AC, et al. Clinical diagnosis of central venous catheter line infection: a difficult job. Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 29-October 2, 1991; Chicago, Illinois.
46. Safdar N, Maki DG. Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters. Crit Care Med. 2002;30:2632-2635.
47. Dobbins BM, Kite P, Wilcox MH. Diagnosis of central venous catheter related sepsis - a critical look inside. J Clin Pathol. 1999;52:165-172.
48. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249-1272.
49. Capdevila JA, Planes AM, Palomar M, et al. Value of differential quantitative blood cultures in the diagnosis of catheter-related sepsis. Eur J Clin Microbiol Infect Dis. 1992;11:403-407.
50. Cicalini S, Palmieri F, Noto P, et al. Diagnosis of intra vascular catheter-related infection. J Vasc Access. 2002;3:114-119.
51. Dobbins BM, Catton JA, Kite P, McMahon MJ, Wilcox MH. Each lumen is a potential source of central venous catheter-related bloodstream infection. Crit Care Med. 2003;31:1688-1690.
52. Everts R, Harding H. Catheter-drawn blood cultures: is withdrawing the heparin lock beneficial? Pathology. 2004;36:170-173.
53. Guiot HF, Helmig-Schurter AV, van't Noordende JM. The relevance of cultures of catheter-drawn blood and heparin-lock fluid to diagnose infection in hematologic patients. Ann Hematology. 1992;64:28-34.
54. Zaragoza R, Artero A, Camarena JJ, et al. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect. 2003;9:412-418.
55. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37:745-751.
56. Lodise TP, McKinnon PS, Swiderski L, Ryback MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36:1418-1423.
57. von Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs. 2005;65:179-214.
58. Bestul MB, Vandenbussche HL. Antibiotic lock technique: review of the literature. Pharmacotherapy. 2005;25:211-227.
59. Segarra-Newnham M, Martin-Cooper EM. Antibiotic lock technique: a review of the literature. Ann Pharmacother. 2005;39:311-318.
60. Koldehoff M, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents. 2004;24:491-495.
61. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol. 2003;25:616-621.
62. Barbaric D, Curtin J, Pearson L, Shaw PJ. Role of hydrochloric acid in the treatment of central venous catheter infections in children with cancer. Cancer. 2004;101:1866-1872.
63. Chatzinikolaou I, Zipf TF, Hanna H, et al. Minocycline- ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. Clin Infect Dis. 2003;36:116-119.
64. Ryder M, Nishikawa R, Liu YL, et al. Tetra sodium EDTA: a novel antimicrobial agent superior to ciprofloxacin in eradicating biofilm bacteria: implications for catheter-related bloodstream infections [abstract]. J Parenter Enteral Nutr. 2005;29:S18.
65. Percival SL, Kite P, Eastwood K, et al. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infect Control Hosp Epidemiol. 2005;26:515-519.
66. Kite P, Eastwood K, Sugden S, et al. Use of in vivo generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J Clin Microbiol. 2004;42:3073-3076.